论文部分内容阅读
难治性成人急性白血病(RAAL)15例,年龄范围15—74岁,平均52岁,6例为ANLL复发;5例为ALL复发;3例系由MDS转为ANLL;1例系多发性骨髓瘤经马法兰治疗4年后,转为ANLL。开始的9个病人用环磷酰胺350mg/m~2,24小时静脉输注,连续5天;Ara-C 100mg/m~2,静脉冲注,Q12h,10次;VCR2mg,静脉冲注,第一天;强的松100mg/日,口服,连续7天。后来的6个病人,环磷酰胺增至7天;Ara-C增至14次。所有病人都给予有力的支持疗法,包括应用抗生素、对有感染和血小板减少者分别输注粒细胞和血小板。
Fifteen patients with refractory adult acute leukemia (RAAL), ranging in age from 15 to 74 years (mean 52 years), 6 had an ANLL recurrence, 5 had ALL relapse, 3 had MDS to ANLL, and 1 had multiple bone marrow Four years after treatment with melphalan, the tumors were switched to ANLL. The first 9 patients were treated with cyclophosphamide 350mg / m ~ 2,24 hours intravenously for 5 consecutive days; Ara-C 100mg / m ~ 2, intravenous injection, Q12h, 10 times; VCR2mg, One day; prednisone 100mg / day, orally, for 7 days. The subsequent six patients, cyclophosphamide increased to 7 days; Ara-C increased to 14 times. All patients are given strong supportive therapy, including the use of antibiotics, were infected and thrombocytopenia, respectively, infusions of granulocytes and platelets.